News

Filter by year:

11/06/2019

Passage Bio to Present at Barclays Gene Editing & Gene Therapy Summit

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, chief operating officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Wednesday, November 13th, 2019 at 9:30 a.m. ET in New York, NY.

10/29/2019

Passage Bio Appoints Richard Morris as Chief Financial Officer

Our partner, Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointment of Richard Morris as chief financial officer.

10/10/2019

Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day

Dr. Jim Wilson is a guest today at Amicus’ 2019 Analyst Day which will highlight the portfolio of novel therapies for rare metabolic diseases.

10/01/2019

Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019

Our partner, Amicus Therapeutics today announced upcoming presentations at the following medical and investor conferences in October 2019.

9/23/2019

Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the appointments of Gary Romano, M.D., Ph.D, as chief medical officer and Edgar (Chip) Cale, J.D., as general counsel.

9/09/2019

Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP). The license is for the clinical development of a potential treatment for patients with Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).